Risk stratification for cervical neoplasia using extended high‐risk HPV genotyping in women with ASC‐US cytology: A large retrospective study from China

2021 ◽  
Author(s):  
Xiang Tao ◽  
R. Marshall Austin ◽  
Ting Yu ◽  
Fangfang Zhong ◽  
Xianrong Zhou ◽  
...  
Keyword(s):  
Retrospective Study ◽  
High Risk ◽  
Risk Stratification ◽  
Cervical Neoplasia ◽  
Hpv Genotyping ◽  
High Risk Hpv ◽  
Large Retrospective Study

scholarly journals Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?

2016 ◽  
Vol 27 (6) ◽  
Author(s):  
Yeoun Eun Sung ◽  
Eun Young Ki ◽  
Youn Soo Lee ◽  
Soo Young Hur ◽  
Ahwon Lee ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Risk Stratification ◽  
Hpv Infection ◽  
Hpv Genotyping ◽  
High Risk Hpv

36. Anal cytology and HPV genotyping in women with lower genital tract neoplasia

Sexual Health ◽  
2013 ◽  
Vol 10 (6) ◽  
pp. 587 ◽  
Author(s):  
Katina Robison ◽  
Beth Cronin ◽  
Christine Luis ◽  
Paul DiSilvestro ◽  
Melissa Clark
Keyword(s):  
High Risk ◽  
Genital Tract ◽  
Exposed Group ◽  
Control Group ◽  
High Grade ◽  
Hpv Genotyping ◽  
Lower Genital Tract ◽  
Anal Cytology ◽  
History Of ◽  
High Risk Hpv

Objective To compare the prevalence of abnormal anal cytology and high-risk HPV among women with a recent history of HPV-related genital neoplasia to women without a history of HPV-related genital neoplasia. Methods: A cross-sectional pilot study was performed. Women with a history of high-grade cervical, vulvar, or vaginal dysplasia or cancer within the past 2 years were eligible for the exposed group. Women without a history of high-grade anogenital dysplasia or cancer were eligible for the control group. Anal cytology and HPV genotyping were performed after informed consent was obtained. Results: 127 women were enrolled in the exposed group and 45 in the control group. The control group was slightly older and less likely to be current smokers. There was no difference between groups in history of anal intercourse. Forty-four per cent of the exposed group had abnormal anal cytology compared with 21.6% of the control group (P = 0.03). High-risk HPV was detected in the anal canal of 6 in the exposed group compared with none in the control group (P = 0.2). Fourteen per cent of the anal cytology results were read as insufficient in both groups. HPV results were insufficient in 29.2% of exposed versus 43.5% of control (P = 0.2). Conclusions: Women with a history of lower genital tract dysplasia are more likely to have a positive anal cytology result compared with women without a history. Additional information is needed to determine the best method of anal cancer screening among women with a history of lower genital tract dysplasia.

scholarly journals p16INK4a Expression Correlates with Degree of Cervical Neoplasia: A Comparison with Ki-67 Expression and Detection of High-Risk HPV Types

2003 ◽  
Vol 16 (7) ◽  
pp. 665-673 ◽  
Author(s):  
S Nicholas Agoff ◽  
Patricia Lin ◽  
Janice Morihara ◽  
Constance Mao ◽  
Nancy B Kiviat ◽  
...  
Keyword(s):  
High Risk ◽  
Cervical Neoplasia ◽  
Ki 67 ◽  
P16ink4a Expression ◽  
Hpv Types ◽  
High Risk Hpv

Human papillomavirus genotyping using HPV DNA chip analysis in Korean women

2007 ◽  
Vol 17 (2) ◽  
pp. 497-501 ◽  
Author(s):  
H. S. Lee ◽  
K. M. Kim ◽  
S. M. Kim ◽  
Y. D. Choi ◽  
J. H. Nam ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Cervical Neoplasia ◽  
Dna Chip ◽  
Korean Women ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Hpv Genotypes ◽  
High Risk Hpv ◽  
Chip Analysis

This study was designed to investigate the genotypes of human papillomavirus (HPV) in Korean women who had abnormal cervical cytology and to evaluate the clinical accuracy of HPV DNA chip analysis for the diagnosis of cervical neoplasia. Liquid-based cytology preparations, HPV DNA chip analysis, and cervical biopsy were performed in 2358 women. High-risk HPV was identified in 23.5% of 1650 histologically confirmed normal samples (including cervicitis and squamous metaplasia) and in 81.8% of 708 samples with cervical intraepithelial neoplasia (CIN) and carcinoma (P< 0.01). The major prevalent high-risk HPV genotypes in 381 samples of CIN II/III were HPV-16, -58, -33, and -31, in order of prevalence rate (average overall, 78.0%), and HPV-16, -18, -58, and -33 (average overall, 81.2%) in 133 samples of squamous cell carcinoma (SCC). The infection rate of HPV-16 was significantly higher than that of other high-risk HPV genotypes in all normal, CIN, and SCC cases (P< 0.01) and increased with more advanced squamous cervical lesions (P< 0.01). The detection accuracy of high-risk HPV using HPV DNA chip analysis for CIN II or worse was as follows: sensitivity 84% (81–87%), specificity 72% (70–74%), positive predictive value 47% (44–50%), and negative predictive value 94% (92–95%). These results suggest that HPV DNA chip analysis may be a reliable diagnostic tool for the detection of cervical neoplasia and that there are geographic differences in the distribution of high-risk HPV genotypes.

scholarly journals Evaluation of the SureX HPV Genotyping Test for the Detection of High-Risk HPV in Cervical Cancer Screening

2020 ◽  
Author(s):  
Baojun Wei ◽  
Ping Mei ◽  
Shengkai Huang ◽  
Xueting Yu ◽  
Tong Zhi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
Agreement Rate ◽  
Hpv Genotyping ◽  
Hpv Test ◽  
Hpv Types ◽  
High Risk Hpv

Abstract Background: The SureX HPV genotyping test (SureX HPV test), which targets the human papillomavirus (HPV) E6/E7 genes was compared with the Cobas 4800 and Venus HPV tests for detecting 14 high-risk HPV (HR-HPV) types in clinical referral and follow-up patients to evaluate its value for cervical cancer screening.Methods: Two different populations were enrolled in the study. The first population comprised 185 cases and was used for comparing the SureX HPV test (Health, China) with the Cobas 4800 test (Roche, USA). The second population comprised 290 cases and was used for comparing the SureX HPV test (Health, China) with the Venus HPV test (Zhijiang, China). Polymerase chain reaction (PCR) sequencing was performed for further confirmation of discordant results.Results: In the first population, the overall agreement rate was 95.3% for 14 High-Risk HPV types. Eight discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 75.0% between the SureX HPV test and PCR sequencing and 25.0% between the Cobas 4800 test and PCR sequencing (P<0.01). In the second population, the overall agreement rate was 94.5%. Thirteen discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 76.9% between the SureX HPV test and PCR sequencing and 23.1% between the Venus HPV test and PCR sequencing (P<0.01). With cervical intraepithelial neoplasia grade 2+ (CIN2+) as the reference standard, the sensitivity values of the SureX HPV test and the Venus HPV test were 93.5% and 92.0%, (P>0.05), while the specificity values were 43.3% and 46.7%, respectively (P>0.05).Conclusion: The SureX HPV test had good consistency with both the Cobas 4800 and Venus HPV tests for 14 HR-HPV types. In addition, it avoided some false negatives and false positives. Therefore, the SureX HPV test can be used for cervical cancer screening.

scholarly journals Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia

2020 ◽  
pp. 1-8
Author(s):  
Haitham Kussaibi ◽  
Reem Al Dossary ◽  
Ayesha Ahmed ◽  
Aroub Muammar ◽  
Raghad Aljohani
Keyword(s):  
Saudi Arabia ◽  
Retrospective Study ◽  
High Risk ◽  
Pap Test ◽  
Eastern Province ◽  
Hpv Genotypes ◽  
High Risk Hpv

scholarly journals RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues

2019 ◽  
Vol 33 (4) ◽  
pp. 748-757 ◽  
Author(s):  
Corina N. A. M. van den Heuvel ◽  
Diede L. Loopik ◽  
Renée M. F. Ebisch ◽  
Duaa Elmelik ◽  
Karolina M. Andralojc ◽  
...  
Keyword(s):  
High Risk ◽  
Transcriptional Activity ◽  
Hpv Genotyping ◽  
High Risk Hpv

In Vitro Nucleic Acid Hybridization for the Identification of High-Risk Human Papillomavirus (HPV) in Cervical Clinical Specimens

2019 ◽  
Vol 42 ◽  
pp. 51-58
Author(s):  
N.A. Parmin ◽  
Uda Hashim ◽  
Wan Azani Mustafa ◽  
S.C.B. Gopinath ◽  
Zulida Rejali ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
High Risk ◽  
Test Specimen ◽  
Pap Smear ◽  
Nucleic Acid Hybridization ◽  
Clinical Specimens ◽  
Hpv Dna ◽  
Hpv Genotyping ◽  
High Risk Hpv

The reliability and specificity of the Pap smear rely on the eyewitness to perceive and an assortment of cell variations in clinically obtained cervical specimens. The improvement in early diagnosis to distinguish Human Papillomavirus (HPV) infection has been an issue. ELISA has been intended to analyze the immune response against HPV, and they can be utilized to distinguish the phase of the infection. The objective of this study to characterize the performance of In Vitro Nucleic Acid Hybridization with a correlation with Liquid-Based Cytology and HPV DNA Genotyping Test to assess its use as the potential for the identification of high-risk HPV in cervical clinical specimens. Hybridization utilizing an in vitro nucleic acid DNA-based ELISA method was performed with an improved chemiluminescent for the qualitative and semi-quantitative identification of high-risk HPV in cervical specimens. For analyzing the reliability to identify HPV DNA in cervical Pap smear, we studied the effectiveness of FDA-approved Hybrid Capture II (HCII) utilizing cervical swapping from 20 patient clinical specimens. Two scrapes-outs were positive for the occurrence of HPV. Only specimens displayed positive with HCII test were further confirmed by HPV Genotyping Test. Specimen 2 and 13 were positive for one of the 13 high-risk types in HCII test. Specimen 2 was confirmed by HPV genotyping test as a positive high-risk HPV type 58.

Sign in / Sign up

Export Citation Format

Share Document